癌症治疗中的DNA损伤反应抑制剂:过去的经验教训,目前的状况和未来的影响
Yvette Drew1, Frank T Zenke2, Nicola J Curtin3
1BC Cancer Vancouver Centre and Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Nature reviews. Drug discovery
|November 12, 2024
概括
对DNA损伤反应 (DDR) 的缺陷会导致癌症的脆弱性. 从PARP抑制剂中吸取的教训可以指导开发新的DDR向药物,提高癌症治疗的成功率.
科学领域:
- 瘤学 在瘤学方面.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 通过协调DNA修复和细胞周期检查点,DNA损伤反应 (DDR) 网络保持了基因组的稳定性.
- DDR缺陷导致基因组不稳定性和瘤发展,但也存在治疗漏洞.
- PARP 抑制剂利用瘤中的同源重组修复缺陷,导致已批准的疗法.
研究的目的:
- 分析从用于DDR向药物的PARP抑制剂开发中学到的经验教训.
- 探索其他DDR抑制剂类别有限成功的原因.
- 建议改进开发新型DDR向癌症疗法的策略.
主要方法:
- 对DDR抑制剂的历史和当前临床试验设计的审查.
- 对DDR向疗法的预测生物标志物要求的分析.
- 探索单疗法和组合研究模型,包括与抗血管原或免疫检查点抑制剂的组合.
主要成果:
- 尽管进行了广泛的研究,但只批准了PARP抑制剂,很少有其他DDR抑制剂达到后期试验阶段.
- 对于更可靠的预测生物标志物来指导DDR向治疗选择,存在着极大的需求.
- 目前的研究设计可能不适合评估新型DDR抑制剂.
结论:
- 利用PARP抑制剂开发的见解对于推进新的DDR向药物至关重要.
- 改进的生物标志物策略和创新的临床试验设计对于治疗成功至关重要.
- 同时针对多个DDR途径和组合策略的同时向有望改善癌症治疗.
相关概念视频
02:37DNA Damage can Stall the Cell Cycle
9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:37DNA Damage Can Stall the Cell Cycle
2.6K
2.6K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K